{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:07:05Z","timestamp":1790042825699,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.2165\/11634580-000000000-00000","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T21:18:52Z","timestamp":1362518332000},"page":"121-126","source":"Crossref","is-referenced-by-count":110,"title":["Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex"],"prefix":"10.1007","volume":"12","author":[{"given":"Mary Kay","family":"Koenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Slopis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,18]]},"reference":[{"key":"12030121_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"R.A. Schwartz","year":"2007","unstructured":"Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007; 57: 189\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jaad.2004.01.016","volume":"51","author":"Y. Kane","year":"2004","unstructured":"Kane Y. The \u201cbumps\u201d on my face. J Am Acad Dermatol 2004; 51: S11\u20132","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bjps.2005.04.021","volume":"58","author":"K.A. El-Musa","year":"2005","unstructured":"El-Musa KA, Shehadi RS, Shehadi S. Extensive facial adenoma sebaceum: successful treatment with mechanical dermabrasion: case report. Brit J Plast Surg 2005; 58: 1143\u20137.","journal-title":"Brit J Plast Surg"},{"key":"12030121_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2230.1998.00371.x","volume":"23","author":"T.M. Finch","year":"1998","unstructured":"Finch TM, Hindson C, Cotterill JA. Successful treatment of adenoma sebaceum with the potassium titanyl phosphate laser. Clin Exp Dermatol 1998; 23: 201\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"12030121_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.sap.0000221621.34715.21","volume":"57","author":"K. Hori","year":"2006","unstructured":"Hori K, Soejima K, Nozaki M, et al. Treatment of facial angiofibromas of tuberous sclerosis using cultured epithelial autografts. Ann Plast Surg 2006; 57: 415\u20137.","journal-title":"Ann Plast Surg"},{"key":"12030121_CR6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/0190-9622(95)91814-0","volume":"33","author":"A.J. Kaufman","year":"1995","unstructured":"Kaufman AJ, Grekin RC, Geisse JK, et al. Treatment of adenoma sebaceum with the copper vapor laser. J Am Acad Dermatol 1995; 33: 770\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR7","first-page":"337","volume":"147","author":"E. Papadavid","year":"2002","unstructured":"Papadavid E, Markey A, Bellaney G, et al. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Brit J Plast Surg 2002; 147: 337\u201342.","journal-title":"Brit J Plast Surg"},{"key":"12030121_CR8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00006534-199610000-00003","volume":"98","author":"C.N. Verheyden","year":"1996","unstructured":"Verheyden CN. Treatment of the facial angiofibromas of tuberous sclerosis. Plast Reconstr Surg 1996; 98: 777\u201383.","journal-title":"Plast Reconstr Surg"},{"key":"12030121_CR9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1067\/mjd.2001.116223","volume":"45","author":"R.C. Bittencourt","year":"2001","unstructured":"Bittencourt RC, Huilgol SC, Seed PT, et al. Treatment of angiofibromas with scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up. J Am Acad Dermatol 2001; 45: 731\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR10","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.0712397105","volume":"105","author":"S. Li","year":"2008","unstructured":"Li S, Takeuchi F, Wang J, et al. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamaratomas. PNAS 2008; 105: 3539\u201344.","journal-title":"PNAS"},{"key":"12030121_CR11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jaad.2004.01.009","volume":"51","author":"T.N. Darling","year":"2004","unstructured":"Darling TN. Hamartomas and tubers from defects in harmartin-tuberin. J Am Acad Dermatol 2004; 51: S9\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"J.J. Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, et al. Rapamycin for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med 2008; 358: 140\u201351.","journal-title":"New Engl J Med"},{"key":"12030121_CR13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"D.N. Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490\u20138.","journal-title":"Ann Neurol"},{"key":"12030121_CR14","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0883073808321764","volume":"23","author":"M.K. Koenig","year":"2008","unstructured":"Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cells astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008; 23: 1238\u20139.","journal-title":"J Child Neurol"},{"key":"12030121_CR15","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.rmed.2010.03.017","volume":"104","author":"C.G. Glasgow","year":"2010","unstructured":"Glasgow CG, Steagall WK, Taveira-DaSilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Resp Med 2010; 104: S45\u201358.","journal-title":"Resp Med"},{"key":"12030121_CR16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","volume":"57","author":"K.V. Paghdal","year":"2007","unstructured":"Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007; 57: 1046\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"12030121_CR17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/088307389901400610","volume":"14","author":"E.S. Roach","year":"1999","unstructured":"Roach ES, DiMario FJ, Kandt RS, et al. Tuberous sclerosis consensus conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: 401\u20137.","journal-title":"J Child Neurol"},{"key":"12030121_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","volume":"53","author":"R.S. Foster","year":"2012","unstructured":"Foster RS, Bint LJ, Halbert AR. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol 2012; 53: 52\u20136.","journal-title":"Australas J Dermatol"},{"key":"12030121_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D36TB7N61M","volume":"18","author":"T. Truchuelo","year":"2012","unstructured":"Truchuelo T, Diaz-Ley B, Rios L, et al. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J 2012; 18: 15.","journal-title":"Dermatol Online J"},{"key":"12030121_CR20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","volume":"148","author":"M. Wataya-Kaneda","year":"2012","unstructured":"Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol 2012; 148: 138\u20139.","journal-title":"Arch Dermatol"},{"key":"12030121_CR21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archdermatol.2011.254","volume":"147","author":"C.M. DeKlotz","year":"2011","unstructured":"DeKlotz CM, Ogram AE, Singh S, et al. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol 2011; 147: 1116\u20137.","journal-title":"Arch Dermatol"},{"key":"12030121_CR22","doi-asserted-by":"crossref","unstructured":"Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J Eur Acad Dermatol Venereol. Epub 2011 Aug 11","DOI":"10.1111\/j.1468-3083.2011.04212.x"},{"key":"12030121_CR23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ad.2011.02.019","volume":"103","author":"P. Valeron-Almazan","year":"2012","unstructured":"Valeron-Almazan P, Vitiello M, Abuchar A, et al. Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis. Actas Dermosifiliogr 2012; 103: 165\u20136.","journal-title":"Actas Dermosifiliogr"},{"key":"12030121_CR24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","volume":"165","author":"M.M. Mutizwa","year":"2011","unstructured":"Mutizwa MM, Berk DR, Anadkat MJ. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mg mL\u22121) in two patients with tuberous sclerosis. Br J Dermatol 2011; 165: 922\u20133.","journal-title":"Br J Dermatol"},{"key":"12030121_CR25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","volume":"165","author":"M. Wataya-Kaneda","year":"2011","unstructured":"Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol 2011; 165: 912\u20136.","journal-title":"Br J Dermatol"},{"key":"12030121_CR26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2010.489598","volume":"23","author":"E. Kaufman McNamara","year":"2012","unstructured":"Kaufman McNamara E, Curtis AR, Fleischer Jr AB. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat 2012; 23: 46\u20138.","journal-title":"J Dermatolog Treat"},{"key":"12030121_CR27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","volume":"146","author":"A.K. Haemel","year":"2010","unstructured":"Haemel AK, O\u2019Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146: 715\u20138.","journal-title":"Arch Dermatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2165\/11634580-000000000-00000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T04:36:16Z","timestamp":1644467776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/11634580-000000000-00000"}},"subtitle":["A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"aliases":["10.1007\/bf03262196"],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["12030121"],"URL":"https:\/\/doi.org\/10.2165\/11634580-000000000-00000","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}